Cite

HARVARD Citation

    Moiseenko, F. et al. (n.d.). 42PPrediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy. Annals of oncology. p. . [Online]. 
  
Back to record